Theravance Biopharma (TBPH) experienced significant financial improvement in 2025 following years of operating losses linked to clinical development challenges. The company saw a strong rebound with $20 million operating income and $61 million net income, driven largely by steady growth in YUPELRI revenue despite competition and pricing pressures. However, setbacks such as the failure of a pivotal Phase 3 multiple system atrophy (MSA) study have prompted workforce reductions and underscore ongoing pipeline uncertainties. With ample liquidity and strategic cost management, Theravance aims to stabilize its performance while navigating patent litigation risks and competitive dynamics.